ArticleJournal of pharmaceutical policy and practice2021
Drug supply situation in Rwanda during COVID-19: issues, efforts and challenges.
Article in Journal of pharmaceutical policy and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Impact of drug shortages on the work of hospital pharmacists in Japan.Journal of pharmaceutical policy and practice · 2026Article
- Factors contributing to human and veterinary medicine shortages in developing countries: perspectives of suppliers and regulators in Namibia.Tropical medicine and health · 2025Article
- Disruptions in Tiopronin therapy: impacts on clinical outcomes of pediatric cystinuria patients during the COVID-19 pandemic.Urolithiasis · 2025Article
- Applying a Theory of Change for Human Resources Development in Public Health Supply Chains in Rwanda.Global health, science and practice · 2025Article
- A qualitative exploration of purchasing, stockpiling, and use of drugs during the COVID-19 pandemic in an urban city of Bangladesh.Public health in practice (Oxford, England) · 2024Article
- Accessibility of malaria commodities in Geita District Council, mainland Tanzania: the experiences from healthcare providers and clients.Journal of pharmaceutical policy and practice · 2024Article
- Article
- Impact of COVID-19 on the supply chain of essential health commodities: a mixed method study, in Dar es Salaam, Tanzania.Journal of pharmaceutical policy and practice · 2023Article
- The knock-on effects of COVID-19 pandemic on the supply and availability of generic medicines in Ethiopia: mixed methods study.BMC health services research · 2023Article
- Continuity of CVD treatment during the COVID-19 pandemic: evidence from East Java, Indonesia.Journal of pharmaceutical policy and practice · 2023Article
- The Quality Management Improvement Approach: Successes and Lessons Learned From a Workforce Development Intervention in Rwanda's Health Supply Chain.Global health, science and practice · 2023Article
- Analysis of pharmaceutical inventory management based on ABC-VEN analysis in Rwanda: a case study of Nyamagabe district.Journal of pharmaceutical policy and practice · 2023Article
- Impact of COVID-19 on access to cancer care in Rwanda: a retrospective time-series study using electronic medical records data.BMJ open · 2022Article
- Revisiting the issue of access to medicines in Africa: Challenges and recommendations.Public health challenges · 2022Review
- The impact of COVID-19 on communicable and non-communicable diseases in Africa: a narrative review.Le infezioni in medicina · 2022Review
- Article
- "We face the same risk as the other health workers": Perceptions and experiences of community pharmacists in Indonesia during the COVID-19 pandemic.PLOS global public health · 2022Article
- Patients Access to Medicines - A Critical Review of the Healthcare System in Kenya.Risk management and healthcare policy · 2022Review
- The Particularities of Pharmaceutical Care in Improving Public Health Service during the COVID-19 Pandemic.International journal of environmental research and public health · 2021Review
- Pharmacoeconomics in Africa: needs, prospect and challenges.Journal of pharmaceutical policy and practice · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a threat to health systems around the world and Rwanda is not an exception. The impact of the pandemic is far-reaching and access to health commodities is not spared. Proper drug supply is critical for a robust healthcare system. It determines the extent at which the population are likely to have access to essential medicines and treatments. In Rwanda, the pharmaceutical sector heavily relies on imports. With the emergence of COVID-19 pandemic, the drug supply system was interrupted leaving many stores from small local pharmacies to the big medical stores running out of stock. The reasons were limited importation of goods from abroad, and the panic buying practice among the customers and some institutions when responding to the pandemic. Drug and medicines accessibility, availability and affordability should be the core of any drug management policy. It is with no doubt that, Rwanda has made a tremendous work to mitigate the effect of COVID-19 on the country's drug supply; however, efforts are still needed to invest in local pharmaceutical production as a way to minimize import expenses in the country. Good policy on drug importation, production and distribution should be enforced to avoid any drug shortage that may be encountered in the Rwandan drug market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.